While we can’t say that AstraZeneca (NYSE: AZN) who reported results this morning has done much right when it comes to diabetes their results are almost a perfect picture as to what the diabetes drug market has become. A market that has fully commoditized and become a battle of rebates combined with discounts. Astra also reflects many of the mistakes made in this market and how these mistakes force companies to make critical choices.
It’s ironic that Bydureon, the company’s once-weekly GLP-1 and the product that brought them into the diabetes drug market has become . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.